medigraphic.com
Colegio de Medicina Interna de México.

2025, Number 06

<< Back Next >>

Med Int Mex 2025; 41 (06)

Prevalence and factors associated with complications in patients with transcatheter aortic valve replacement at a tertiary care center

Lugo OE, Martínez HFA, Zazueta AV, Bernal MAD, Lugo MJA

Language: Spanish
References: 33
Page: 311-322
PDF size: 402.40 Kb.


ABSTRACT

Objective: To analyze the prevalence and factors associated with complications and mortality in patients undergoing aortic valve implantation.
Materiales and Methods: Observational, retrospective, cross-sectional and analytical study was done from 2017 to 2023 in patients with aortic stenosis undergoing transcatheter aortic valve replacement. Demographic, clinical and intervention variables were collected.
Results: Seventy cases were included, mean age 75 ± 9.3 years, 44 were men. A prevalence of 41 cases of complications during 8 years and a hospital mortality of 14 was found. The most frequent associated comorbidities were arterial hypertension alone (n = 20), diabetes mellitus and dyslipidemia (n = 17). Complications were conduction and rhythm disorders in 11 patients. There was an association between the need for a pacemaker and the outcome (p = 0.000); outcome and complications with a p value = 0.05 (p ≤ 0.05), type of device (p= 0.032), need for a pacemaker (p = 0.001) and type of device and complications (p = 0.039).
Conclusions: Transcatheter aortic valve replacement has been shown to be effective in patients with degenerative aortic stenosis, although with a significant rate of complications and mortality. Hypertension and diabetes were common, and the need for pacemakers was associated with worse outcomes.


REFERENCES

  1. Santangelo G, Bursi F, Faggiano A, Moscardelli S, et al.The global burden of valvular heart disease: from clinicalepidemiology to management. J Clin Med 2023; 12: 1-20.https//:doi.org.10.3390/jcm12062178

  2. Avvedimento M, Angellotti D, Ilardi F, Leone A, et al. Acuteadvanced aortic stenosis. Heart Fail Rev 2023; 1101-11.https//:doi.org.10.1007/s10741-023-10312-7

  3. Shah SM, Shah J, Lakey SM, Garg P, Ripley DP. Pathophysiology,emerging techniques for the assessment and noveltreatment of aortic stenosis. 2023; 10: 1-10.

  4. Chin CWL. Aortic stenosis: The old disease with new (andevolving) faces. J Am Heart Assoc 2021; 10: 1-3. https//:doi.org.10.1161/JAHA.121.023531

  5. Oh JK, Ito S. Severity of aortic stenosis: A moving target.J Am Coll Cardiol 2022; 80: 677-80. https//:doi.org.10.1016/j.jacc.2022.05.037

  6. Senior R, Khattar RS. Assessment of aortic stenosis: Timeto go with the flow. J Am Coll Cardiol 2020; 75: 1770-1.

  7. Thakur K, Nazif TM, Khalique OK, Paradis JM, Harjai KJ.Transcatheter aortic valve replacement: The year in review2017. J Interv Cardiol 2018; 31: 543-52. https//:doi.org.10.1111/joic.12562

  8. Dasi LP, Hatoum H, Kheradvar A, Zareian R, et al. On themechanics of transcatheter aortic valve replacement. AnnBiomed Eng 2017; 45 (2): 310-31.

  9. Solomonica A, Choudhury T, Bagur R. Newer-generation ofEdwards transcatheter aortic valve systems: SAPIEN 3, Centera,and SAPIEN 3 Ultra. Expert Rev Med Devices 2019; 16(2): 81-7. https//:doi.org.10.1080/17434440.2019.1555465

  10. Athappan G, Gajulapalli RD, Tuzcu ME, Svensson LG,Kapadia SR. A systematic review on the safety of secondgenerationtranscatheter aortic valves. EuroIntervention2016; 11: 1034-43.

  11. Vahanian A, Beyersdorf F, Praz F, Milojevic M, et al. 2021ESC/EACTS Guidelines for the management of valvularheart disease. Eur Heart J 2022; 43 (7): 561-632.

  12. Isselbacher EM, Preventza O, Black JH, Augoustides JG, etal. 2022 ACC/AHA Guideline for the Diagnosis and Managementof Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committeeon Clinical Practice Guidelines. Circulation 2022; 146: E334-482. https://doi.org/10.1161/CIR.0000000000001106

  13. Mazur P, Marin-Cuartas M, Arghami A, Noack T, et al.Operative management after transcatheter aortic valvereplacement. Kardiologia Polska 2023; 81: 107-14.https//:doi.org.10.33963/KP.a2023.0026

  14. Braghiroli J, Kapoor K, Thielhelm TP, Ferreira T, Cohen MG.Transcatheter aortic valve replacement in low risk patients:A review of PARTNER 3 and Evolut low risk trials. CardiovascDiagn Ther 2020; 10: 59-71. https//:doi.org.10.21037/cdt.2019.09.12

  15. Hamm CW, Möllmann H, Holzhey D, Beckmann A, et al.The German Aortic Valve Registry (GARY): In-hospitaloutcome. Eur Heart J 2014; 35 (24): 1588-98. https//:doi.org.10.1093/eurheartj/eht381

  16. Terré JA, George I, Smith CR. Pros and cons of transcatheteraortic valve implantation (TAVI). Ann CardiothoracSurg 2017; 6 (5): 444-52. https//:doi.org.10.21037/acs.2017.09.15

  17. del Val D, Ferreira-Neto AN, Asmarats L, Maes F, et al.Transcatheter aortic valve replacement: relative safetyand efficacy of the procedure with different devices. ExpRev Med Dev 2019; 16: 11-24. https//:doi.org.10.1080/17434440.2019.1552132

  18. Puri R, Chamandi C, Rodriguez-Gabella T, Rodés-Cabau J.Future of transcatheter aortic valve implantation-evolvingclinical indications. Nat Rev Cardiol 2018; 15: 57-65.https//:doi.org.10.1038/nrcardio.2017.116

  19. Kumar V, Sandhu GS, Harper CM, Ting HH, Rihal CS.Transcatheter aortic valve replacement programs: Clinicaloutcomes and developments. J Am Heart Assoc 2020; 9.https://doi.org/10.1161/JAHA.120.015921

  20. Pinar E, de Lara JG, Hurtado J, Robles M, et al. Prospectiveassessment of clinical outcomes of transcatheter aorticvalve implantation in a cohort of patients based on theirrisk profile. REC Interv Cardiol 2023; 5 (2): 102-9. https://doi.org/10.24875/RECICE.M23000363

  21. Patris V, Giakoumidakis K, Argiriou M, Naka K, et al. Factorsassociated with early cardiac complications followingtranscatheter aortic valve implantation with transapicalapproach. Pragmatic Obs Res 2018; 9: 21-7. https//:doi.org.10.2147/POR.S157843

  22. Stepińska J, Czerwińska K, Witkowski A, Dabrowski M, et al.Risk factors for bleeding complications in patients undergoingtranscatheter aortic valve implantation (TAVI). Cardiol J2013; 20 (2): 125-33. https//:doi.org.10.5603/CJ.2013.0024

  23. Mauri V, Reuter K, Körber MI, Wienemann H, et al. Incidence,risk factors and impact on long-term outcome ofpostoperative delirium after transcatheter aortic valve replacement.Front Cardiovasc Med 2021; 8: 1-6. https//:doi.org.10.3389/fcvm.2021.645724

  24. van Ginkel DJ, Brouwer J, van Hemert ND, Kraaijeveld AO,et al. Major threats to early safety after transcatheteraortic valve implantation in a contemporary cohort of realworldpatients. Netherlands Hear J 2021; 29 (12): 632-42.https//:doi.org.10.1007/s12471-021-01638-8

  25. Smulter N, Lingehall HC, Gustafson Y, Olofsson B, EngströmKG. Delirium after cardiac surgery: Incidence and riskfactors. Interact Cardiovasc Thorac Surg 2013; 17: 790-6.https//:doi.org.10.1093/icvts/ivt323

  26. Bakker RC, Osse RJ, Tulen JHM, Kappetein AP, Bogers AJJC.Preoperative and operative predictors of delirium aftercardiac surgery in elderly patients. Eur J Cardiothoracic Surg2012; 41 (3): 544-9. https//:doi.org.10.1093/ejcts/ezr031

  27. Norkiene I, Ringaitiene D, Misiuriene I, Samalavicius R, et al.Incidence and precipitating factors of delirium after coronaryartery bypass grafting. Scand Cardiovasc J 2007; 41(3): 180-5. https//:doi.org.10.1080/14017430701302490

  28. Van Mieghem NM, Tchetche D, Chieffo A, Dumonteil N,et al. Incidence, predictors, and implications of accesssite complications with transfemoral transcatheter aorticvalve implantation. Am J Cardiol 2012; 110 (9): 1361-7.https//:doi.org.10.1016/j.amjcard.2012.06.042

  29. Kadakia MB, Herrmann HC, Desai ND, Fox Z, et al. Factorsassociated with vascular complications in patients undergoingballoon-expandable transfemoral transcatheteraortic valve replacement via open versus percutaneousapproaches. Circ Cardiovasc Interv 2014; 7 (4): 570-6.https//:doi.org.10.1161/CIRCINTERVENTIONS.113.001030

  30. Perrin N, Bonnet G, Leroux L, Ibrahim R, et al. Transcatheteraortic valve implantation: All transfemoral? Update onperipheral vascular access and closure. Front CardiovascMed 2021. https//:doi.org.10.3389/fcvm.2021.747583

  31. Baumgartner H, Falk V, Bax JJ, De Bonis M, et al. 2017 ESC/EACTS Guidelines for the management of valvular heartdisease. Eur Heart J 2017; 38 (36): 2739-86. https//:doi.org.10.1093/eurheartj/ehx391

  32. Otto CM, Nishimura RA, Bonow RO, Carabello BA, etal. 2020 ACC/AHA Guideline for the Management ofPatients With Valvular Heart Disease: A Report of theAmerican College of Cardiology/American Heart AssociationJoint Committee on Clinical Practice Guidelines.Circulation 2021; 143: E72-227. https://doi.org/10.1161/CIR.0000000000000923

  33. Khatri PJ, Webb JG, Rodés-Cabau J, Fremes SE, et al.Adverse effects associated with transcatheter aorticvalve implantation: A meta-analysis of contemporarystudies. Ann Intern Med 2013; 158: 35-46. https//:doi.org.10.7326/0003-4819-158-1-201301010-00007




2020     |     www.medigraphic.com